Dr. Christoph Schatz, PhD

Senior Science Fellow / Targeted Alpha Therapy VI at Bayer AG

Speaker

Christoph did his master thesis research at Harvard Medical School in Boston. He received his PhD from EMBL in Heidelberg, Germany. In 2003 Christoph joined the Biotech Epiontis working on biomarkers for immunotherapy and moved on to the oncology group at Bayer in 2006. He has profound knowledge in drug development and translational science. In the last seven years Christoph was leading preclinical research teams driving the development of radiolabeled conjugates for the treatment of cancer from the preclinical stage into early clinical development. Christoph is currently a Senior Scientist at the Bayer Research site in Berlin, Germany.